RNAZ
Transcode Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.73
+0.00%Oct 28, 2026, 20:30 UTC
TransCode Therapeutics’ board initiated a formal strategic process to evaluate alternatives intended to maximize value, including licensing, development partnerships and other transactions involving the company and its oncology portfolio.
Source:Oct 19, 2026, 12:04 UTC
Transcode Therapeutics, Inc. announced that a poster on its TTX-MC138 Phase 1a clinical evaluation was accepted for presentation at the Transcode Therapeutics, Inc. in Madrid on October 23, 2026.
Source:Oct 13, 2026, 11:30 UTC
Natera, Inc. and Transcode Therapeutics, Inc. announced a collaboration to support enrollment in TransCode’s Phase 2a trial of TTX-MC138 in patients with colorectal cancer.
Source:Sep 28, 2026, 12:04 UTC
TransCode Therapeutics reported updated Phase 1a clinical trial follow-up data for TTX-MC138 in heavily pretreated patients with advanced solid tumors, showing a 71.4% stable disease rate among 14 efficacy-evaluable patients and no dose-limiting toxicities.
Source:Sep 10, 2026, 20:10 UTC
TransCode Therapeutics announced the retirement of its Chief Financial Officer Tom Fitzgerald and the appointment of John Tattory as Interim Chief Financial Officer.
Source:Aug 31, 2026, 12:05 UTC
TransCode Therapeutics announced the publication of a peer-reviewed article in Cancers reporting that its lead therapeutic candidate TTX-MC138 produced significant survival benefits in a preclinical model of breast cancer bone metastasis.
Source:Jul 22, 2026, 05:03 UTC
TransCode Therapeutics stockholders approved proposals to authorize the issuance of common stock and increase shares under the equity incentive plan at the reconvened annual meeting.
Source:Jun 3, 2026, 12:04 UTC
TransCode Therapeutics completed Phase 1a clinical trial of TTX-MC138 in metastatic cancer, reporting safety and disease stabilization data.
Source: